NL8005072A - Werkwijze ter bereiding van een antibioticum. - Google Patents
Werkwijze ter bereiding van een antibioticum. Download PDFInfo
- Publication number
- NL8005072A NL8005072A NL8005072A NL8005072A NL8005072A NL 8005072 A NL8005072 A NL 8005072A NL 8005072 A NL8005072 A NL 8005072A NL 8005072 A NL8005072 A NL 8005072A NL 8005072 A NL8005072 A NL 8005072A
- Authority
- NL
- Netherlands
- Prior art keywords
- sodium salt
- fur
- acetoxymethyl
- solution
- water
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 16
- 230000003115 biocidal effect Effects 0.000 title description 8
- 239000003242 anti bacterial agent Substances 0.000 title description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 63
- 239000000243 solution Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 39
- 239000011928 denatured alcohol Substances 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 238000002329 infrared spectrum Methods 0.000 claims description 11
- 239000012453 solvate Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 235000015096 spirit Nutrition 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 210000005075 mammary gland Anatomy 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 4
- 238000005169 Debye-Scherrer Methods 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 229910017052 cobalt Inorganic materials 0.000 claims description 3
- 239000010941 cobalt Substances 0.000 claims description 3
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 239000006286 aqueous extract Substances 0.000 claims description 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 239000000284 extract Substances 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 239000000047 product Substances 0.000 description 21
- 238000001914 filtration Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 229940124587 cephalosporin Drugs 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 229930186147 Cephalosporin Natural products 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- -1 cephalosporin compound Chemical class 0.000 description 6
- 150000001780 cephalosporins Chemical class 0.000 description 5
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229940075507 glyceryl monostearate Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical class [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 2
- 229940083916 aluminum distearate Drugs 0.000 description 2
- RDIVANOKKPKCTO-UHFFFAOYSA-K aluminum;octadecanoate;hydroxide Chemical compound [OH-].[Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O RDIVANOKKPKCTO-UHFFFAOYSA-K 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001030 gas--liquid chromatography Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HCJIHHSBMCGTGF-TWGQIWQCSA-N (2z)-2-(furan-2-yl)-2-methoxyiminoacetyl chloride Chemical compound CO\N=C(/C(Cl)=O)C1=CC=CO1 HCJIHHSBMCGTGF-TWGQIWQCSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 102220588815 Stimulator of interferon genes protein_I10Q_mutation Human genes 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 235000012745 brilliant blue FCF Nutrition 0.000 description 1
- 239000004161 brilliant blue FCF Substances 0.000 description 1
- 229940055580 brilliant blue fcf Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical group N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- 239000007765 cera alba Substances 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BLGHDHGFMIZGQQ-YPKPFQOOSA-N ethyl (Z)-2-ethyloctadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCC(CC)C(=O)OCC BLGHDHGFMIZGQQ-YPKPFQOOSA-N 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000010512 hydrogenated peanut oil Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB7931379 | 1979-09-10 | ||
| GB7931379 | 1979-09-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL8005072A true NL8005072A (nl) | 1981-03-12 |
Family
ID=10507735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL8005072A NL8005072A (nl) | 1979-09-10 | 1980-09-09 | Werkwijze ter bereiding van een antibioticum. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4341777A (OSRAM) |
| JP (1) | JPS5645486A (OSRAM) |
| AU (1) | AU6216080A (OSRAM) |
| BE (1) | BE885143A (OSRAM) |
| DE (1) | DE3033868A1 (OSRAM) |
| DK (1) | DK382580A (OSRAM) |
| FR (1) | FR2464960A1 (OSRAM) |
| GB (1) | GB2061922B (OSRAM) |
| IT (1) | IT1128177B (OSRAM) |
| NL (1) | NL8005072A (OSRAM) |
| NZ (1) | NZ194895A (OSRAM) |
| ZA (1) | ZA805556B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60120886A (ja) * | 1983-12-02 | 1985-06-28 | Takeda Chem Ind Ltd | セフェムカルボン酸のナトリウム塩の結晶 |
| US6930983B2 (en) * | 2000-03-15 | 2005-08-16 | Texas Instruments Incorporated | Integrated circuits, systems, apparatus, packets and processes utilizing path diversity for media over packet applications |
| US6911441B2 (en) | 2002-12-16 | 2005-06-28 | Akzo Nobel N.V. | Prolonged release pharmaceutical composition |
| EP3764485A1 (en) | 2019-07-12 | 2021-01-13 | Ratier-Figeac SAS | Brush assembly |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1399086A (en) * | 1971-05-14 | 1975-06-25 | Glaxo Lab Ltd | Cephalosporin compounds |
| US3974153A (en) * | 1971-05-14 | 1976-08-10 | Glaxo Laboratories Limited | 7-Hydrocarbonoxy imino-acetamido-3-carbamoyloxy methylceph-3-em-4 carboxylic acids |
| US3971778A (en) * | 1972-05-12 | 1976-07-27 | Glaxo Laboratories Limited | Cephalosporins having (α-etherified oximino)acylamido groups at the 7-position |
| GB1453049A (en) * | 1973-08-21 | 1976-10-20 | Glaxo Lab Ltd | Cephalosporing antibiotics |
| IT1162442B (it) * | 1978-01-17 | 1987-04-01 | Glaxo Group Ltd | Procedimento per preparare il sale sodico di cefurossima in forma cristallina |
-
1980
- 1980-09-05 US US06/184,383 patent/US4341777A/en not_active Expired - Lifetime
- 1980-09-09 IT IT49634/80A patent/IT1128177B/it active
- 1980-09-09 DK DK382580A patent/DK382580A/da not_active Application Discontinuation
- 1980-09-09 DE DE19803033868 patent/DE3033868A1/de not_active Withdrawn
- 1980-09-09 NZ NZ194895A patent/NZ194895A/xx unknown
- 1980-09-09 ZA ZA00805556A patent/ZA805556B/xx unknown
- 1980-09-09 AU AU62160/80A patent/AU6216080A/en not_active Abandoned
- 1980-09-09 BE BE0/202033A patent/BE885143A/fr not_active IP Right Cessation
- 1980-09-09 GB GB8029059A patent/GB2061922B/en not_active Expired
- 1980-09-09 JP JP12523980A patent/JPS5645486A/ja active Pending
- 1980-09-09 FR FR8019396A patent/FR2464960A1/fr active Granted
- 1980-09-09 NL NL8005072A patent/NL8005072A/nl not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| IT1128177B (it) | 1986-05-28 |
| FR2464960B1 (OSRAM) | 1984-02-10 |
| AU6216080A (en) | 1981-03-19 |
| US4341777A (en) | 1982-07-27 |
| NZ194895A (en) | 1983-07-15 |
| IT8049634A0 (it) | 1980-09-09 |
| DE3033868A1 (de) | 1981-04-02 |
| BE885143A (fr) | 1981-03-09 |
| DK382580A (da) | 1981-03-11 |
| FR2464960A1 (fr) | 1981-03-20 |
| JPS5645486A (en) | 1981-04-25 |
| GB2061922A (en) | 1981-05-20 |
| GB2061922B (en) | 1983-12-14 |
| ZA805556B (en) | 1982-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS5944391A (ja) | 新規なセフロキシムエステル | |
| RS115904A (sr) | Derivati benzena fuzionisani sa azolidinon vinilom | |
| EP3886820B1 (en) | Capsule formulations | |
| JP6851652B2 (ja) | Ｉｄｈｐの冠状動脈アテローム性硬化症の予防及び治療のための薬物又は健康補助食品の調製における応用 | |
| NL8005072A (nl) | Werkwijze ter bereiding van een antibioticum. | |
| JPH023690A (ja) | 抗生物質の安定性の改良 | |
| SE449996B (sv) | (6r,7r)-7-/(z)-2-(2-aminotiazol-4-yl)-2-(2-karboxiprop-2-oxiimino)acetamidol/-3-(1-pyridiniummetyl)cef-3-em-4-karboxylat i form av en kristallin bishydroklorid farmaceutisk komposition derav samt anvendning som mellanpr | |
| US3970651A (en) | Crystalline cephalosporin derivative | |
| SE8003722L (sv) | Penicillansyraderivat, kompositioner innehallande dessa penicillansyraderivat samt forfarande for deras framstellning | |
| US3488729A (en) | Cephalothin ester | |
| EP0180372B1 (en) | Crystalline cephalosporin antibiotics | |
| DE2718730A1 (de) | Cephalosporin-antibiotika | |
| DE3887691T2 (de) | Cephalosporin-antibiotika. | |
| CN104546704A (zh) | 一种奶牛干乳期用盐酸头孢噻呋乳房注入剂及其制备方法 | |
| EP0270503B1 (en) | Utilization of bromure d'otilonium (dci) for topic application in the gastrointestinal tract and relative pharmaceutical formulation appropriate for such use | |
| Durairaj et al. | Establishment of Histomonas meleagridis challenge model in turkeys: An industry perspective. | |
| JP2020505363A (ja) | オキサジン誘導体を含む医薬組成物、およびこの医薬組成物のアルツハイマー病の処置または予防での使用 | |
| US20220193140A1 (en) | Washed platelet extract | |
| CN113307768B (zh) | 喹诺酮类衍生物及其制备方法和用途 | |
| HU195732B (en) | Procecc for the production of medical composition applicable for rectal dosage | |
| RU2824998C2 (ru) | Лекарственные формы в виде капсул | |
| US12227480B1 (en) | 1-(2-(substituted phenyl)-2-oxoethyl)-4-methylpyridin-1-ium bromide as anti-tubercular agents | |
| CN116270635A (zh) | 杂环化合物用于减轻化疗药物引起的不良反应的用途 | |
| JPS59128390A (ja) | セフアロスポリン誘導体及び該誘導体を含有する薬剤 | |
| HK40121602A (en) | Capsule formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A85 | Still pending on 85-01-01 | ||
| BV | The patent application has lapsed |